SCHEMBL6923099

SCHEMBL6923099

CCN(CC)CC(=O)c1cc(C)n(-c2ccc(F)cc2)c1C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.65
NOTUM Q6P988 2/20 0.62
KDM4E B2RXH2 3/20 0.60
USP14 P54578 2/20 0.60
USP7 Q93009 1/20 0.60
RAB9A P51151 8/20 0.59
NPC1 O15118 7/20 0.59
HPGD P15428 3/20 0.59
USP5 P45974 1/20 0.59
LMNA P02545 6/20 0.52
HTT P42858 4/20 0.52
TP53 P04637 1/20 0.52
ALOX15 P16050 1/20 0.52
TSHR P16473 1/20 0.52
ALDH1A1 P00352 5/20 0.50
MITF O75030 3/20 0.49
MAPT P10636 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
HKDC1 Q2TB90 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6923175 0.88 SMN1; SMN2 (0.64) SMN1; SMN2NOTUMKDM4EUSP14USP7
SCHEMBL17282309 0.87 SMN1; SMN2 (0.53) SMN1; SMN2NOTUMKDM4EUSP14USP7
SCHEMBL19501345 0.87 SMN1; SMN2 (0.49) SMN1; SMN2NOTUMKDM4EUSP14USP7
SCHEMBL6921657 0.86 NOTUM (0.65) SMN1; SMN2NOTUMKDM4EUSP14USP7
SCHEMBL19501627 0.84 SMN1; SMN2 (0.58) SMN1; SMN2NOTUMKDM4EUSP14USP7
SCHEMBL6922827 0.82 NOTUM (0.59) SMN1; SMN2NOTUMKDM4EUSP14USP7
SCHEMBL18452326 0.81 ALDH1A1 (0.71) SMN1; SMN2NOTUMKDM4EUSP14USP7
SCHEMBL6922881 0.80 SMN1; SMN2 (0.46) SMN1; SMN2NOTUMKDM4EUSP14USP7
SCHEMBL6921653 0.80 NOTUM (0.60) SMN1; SMN2NOTUMKDM4EUSP14USP7
SCHEMBL6923288 0.80 NOTUM (0.56) SMN1; SMN2NOTUMKDM4EUSP14USP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10351568-B2 Compositions and methods for enhancing proteasome activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2019-07-16 US disclosed
US-9849135-B2 USP14 inhibitors for treating or preventing viral infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-12-26 US disclosed
US-9849135-B2 USP14 inhibitors for treating or preventing viral infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-12-26 US disclosed
EP-2528911-B1 COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY HARVARD COLLEGE (US) 2017-10-25 EP disclosed
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity THE ASSAY DEPOT, INC. 2016-07-28 US disclosed
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity THE ASSAY DEPOT, INC. 2016-07-28 US disclosed
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-18 US disclosed
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-18 US disclosed
WO-2014116228-A1 USP14 INHIBITORS FOR TREATING OR PREVENTING VIRAL INFECTIONS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-07-31 WO disclosed
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-02-21 US disclosed
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-02-21 US disclosed
WO-2011094545-A2 COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351568-B2 Compositions and methods for enhancing proteasome activity PSMG3, PSME3, PSMB11 SMN1; SMN2 307/4885NOTUM 2331/4885KDM4E 2300/4885
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSMB11, PSME3 SMN1; SMN2 307/4885NOTUM 2305/4885KDM4E 2238/4885
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSME3, PSMB11 SMN1; SMN2 307/4885NOTUM 2331/4885KDM4E 2300/4885
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation HSPA2, HSPBP1, HSPH1 SMN1; SMN2 544/4885NOTUM 3253/4885KDM4E 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.